By Steven Reinberg
WEDNESDAY, July 8, 2015 (HealthDay News) — Preliminary trial results suggest that an experimental psoriasis drug may control the chronic skin disease better than the current standard treatment.
The drug, guselkumab, was compared to the commonly used medication adalimumab (Humira, Enbrel) in a study involving nearly 300 patients with plaque psoriasis.
Up to 86 percent of patients who received guselkumab cleared their psoriasis or had minimal psoriasis after 16 weeks of treatment, compared to 58 percent of patients taking adalimumab, the researchers reported.
However, patients getting guselkumab were somewhat more prone to infections, the researchers said.
“As a dermatologist, I am particularly excited about the potential of guselkumab and what this investigational therapy may mean for patients and the treatment of moderate to severe plaque psoriasis in the future,” said lead researcher Dr. Kristian Reich, a partner at Dermatologikum in Hamburg, Germany.
The drug works…
View original post 485 more words